Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13160659 | 0.88 | GPR119 (0.47) | CARM1PRMT6GPR119 | |
| SCHEMBL3343608 | 0.82 | GPR119 (0.52) | CARM1PRMT6GPR119 | |
| SCHEMBL21409412 | 0.81 | CARM1 (0.54) | CARM1PRMT6ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL865044 | 0.81 | GPR119 (0.56) | GPR119ALDH1A1 | |
| SCHEMBL864734 | 0.80 | GPR119 (0.41) | CARM1PRMT6GPR119 | |
| SCHEMBL21409115 | 0.80 | CARM1 (0.48) | CARM1PRMT6GPR119ALDH1A1HTT | |
| SCHEMBL16934608 | 0.78 | GPR119 (0.54) | GPR119ALDH1A1HTT | |
| SCHEMBL867019 | 0.75 | ALDH1A1 (0.52) | GPR119ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL24493334 | 0.75 | CARM1 (0.68) | CARM1PRMT6ALDH1A1EPHX2 | |
| SCHEMBL28870297 | 0.75 | GPR119 (0.50) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| CN-102348703-A | Compounds for the treatment of metabolic disorders | PROSIDION LTD | 2012-02-08 | — | — | CN | disclosed |
| EP-2406247-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103333-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | CARM1 3355/4885PRMT6 2138/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.